BENG SOON MACH(01987.HK):公眾持股量約為23.75%
格隆匯5月17日丨BENG SOON MACH(01987.HK)公吿,於2022年5月12日,Wen Xiaodong購入公司全部已發行股本中2.569億股普通股,佔公吿日期股份約25.69%,每股平均股價約為0.71港元。公司及董事會確認,Wen為獨立第三方。購買事項導致Wen成為香港聯合交易所有限公司上市規則項下公司主要股東及公司核心關連人士,Wen所持股份將不計入公司的公眾持股量。
經考慮Wen及其他公司核心關連人士所持股份,於公吿日期,公司的公眾持股量約為23.75%,低於上市規則第8.08(1)(a)條所規定公眾所持公司全部已發行股本25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.